Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Number of Operating Segments | segment     2    
Proceeds from Divestiture of Interest in Consolidated Subsidiaries     $ 17,824    
Net sales     269,655 $ 257,719  
Gain on sale of Eminence     11,682 $ 0  
Changzhou Eminence Biotechnology [Member]          
Proceeds from Divestiture of Interest in Consolidated Subsidiaries $ 17,800        
Goodwill, Impairment Loss         $ 8,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)         8,600
Protein Sciences [Member]          
Pre-tax restructuring charges     2,200    
Protein Sciences [Member] | Changzhou Eminence Biotechnology [Member]          
Net sales     2,000   4,600
Diagnostics and Genomics [Member]          
Pre-tax restructuring charges         1,400
Wilson Wolf Corporation [Member]          
Payments to Acquire Investments, Total   $ 25,000      
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]          
Forward Contract, Milestone, Annual Revenue Required     92,000    
Forward Contract, Milestone, Annual EBITDA     55,000    
Forward Contract Payment     $ 231,000    
Wilson Wolf Corporation [Member] | First Part of Forward Contract Triggered [Member]          
Noncontrolling Interest, Ownership Percentage by Parent     19.90%    
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]          
Forward Contract, Milestone, Annual Revenue Required     $ 226,000    
Forward Contract, Milestone, Annual EBITDA     136,000    
Forward Contract, Additional Investment     $ 1,000,000    
Forward Contract, Milestone, Multiple for Total Expected Payments     4.4    
Changzhou Eminence Biotechnology [Member]          
Gain on sale of Eminence     $ 11,700    
Inventory Write-down         900
Asset Impairment Charges, Total         $ 900
Changzhou Eminence Biotechnology [Member] | Nonoperating Income (Expense) [Member]          
Gain on sale of Eminence     $ 11,700